Lenzilumab treatment for rare blood cancers are expanding 2023.

A cutting-edge clinical trial for people with a rare blood cancer is being expanded across Australia and potentially beyond. The study is currently underway at  the Royal Adelaide Hospital and the Austin Hospital in Melbourne. Additional sites to be established in New South Wales, Queensland, Victoria, Tasmania. Associate Professor Dan Thomas, the head of the Blood …

Humanigen. The maker of Lenzilumab still hopeful for future . Investors not so much.

The company is trying to find a potential path forward in COVID-19 for the drug and is in talks with platform study groups after a Phase III study did not show statistical significance, but still showed activity. The share price has fallen close to 99 percent in the last year. At one point dipping down …

%d bloggers like this: